Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00364832 · ClinicalTrials.gov registry record · Phase 2
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT00364832 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 137 participants.
The verdict
NCT00364832, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
This study will determine the appropriate dose and frequency of administration of sc Mircera maintenance therapy in dialysis patients with chronic renal anemia who were previously receiving sc epoetin alfa or beta. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Interventions
- DRUG methoxy polyethylene glycol-epoetin beta [Mircera]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2001-10 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00364832
The ClinicalTrials.gov registry entry for NCT00364832 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which methoxy polyethylene glycol-epoetin beta [Mircera] is the first listed.
NCT00364832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00364832 about?
NCT00364832 is a clinical study titled "A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.". This study will determine the appropriate dose and frequency of administration of sc Mircera maintenance therapy in dialysis patients with chronic renal anemia who were previously receiving sc epoetin alfa or beta. The anticipated time on study treatment is 3-12 months and the target sample size is ...
What is the current status of trial NCT00364832?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2001-10. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00364832?
The interventions under investigation include: methoxy polyethylene glycol-epoetin beta [Mircera] (DRUG).
Who is sponsoring clinical trial NCT00364832?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.